NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017

View More View Less
  • 1 From Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Duke Cancer Institute; Yale Cancer Center/Smilow Cancer Hospital; Massachusetts General Hospital Cancer Center; Moffitt Cancer Center; Vanderbilt-Ingram Cancer Center; Stanford Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Mayo Clinic Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Roswell Park Cancer Institute; Huntsman Cancer Institute at the University of Utah; University of Colorado Cancer Center; Fred & Pamela Buffett Cancer Center; City of Hope Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Fox Chase Cancer Center; The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Wisconsin Carbone Cancer Center; University of Michigan Comprehensive Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; and National Comprehensive Cancer Network.
Restricted access

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are also provided for occult primary of the head and neck (H&N), and separate algorithms have been developed by the panel for very advanced H&N cancers. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding the increase in human papillomavirus–associated oropharyngeal cancer and the availability of immunotherapy agents for treatment of patients with recurrent or metastatic H&N cancer.

Provided content development and/or authorship assistance.

Supplementary Materials

    • Supplemental Material (PDF 233 KB)
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 3482 1950 131
PDF Downloads 929 639 52
EPUB Downloads 0 0 0